A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-07-18 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
July 20 Blue Origin NS-16: On the 52nd anniversary of the Apollo 11 Moon landing, Jeff Bezos successfully launches the Blue Origin rocket New Shepard 4 in Van Horn, Texas, carrying himself, his brother Mark, 82-year-old retired pilot Wally Funk, and 18-year-old college student Oliver Daemen. The rocket lands back on Earth within minutes, completing the first crewed spaceflight with reusable rockets. Tom Barrack, founder of Colony Capital and an advisor of Donald Trump, is indicted for making false statements to the FBI and being an unregistered agent for the United Arab Emirates. He is found not guilty in 2022. The Milwaukee Bucks defeat the Phoenix Suns (4–2) in the 2021 NBA Finals to win their first championship since 1971. July 21 The 2021 NHL expansion draft is held at Gas Works Park in Seattle, where the 32nd NHL team, the Seattle Kraken fills out its first ever roster of players. Santa Monica based video game publisher Activision Blizzard, Inc. is hit with a massive lawsuit from the California Department of Fair Employment and Housing after a two-year investigation reveals a "frat boy" like work environment where female employees face sexual harassment, discrimination, and retaliation for speaking out against the company. The Tennessee State Building Commission announces that the statue of Nathan Bedford Forrest will be moved from the Tennessee State Capitol to the Tennessee State Museum. The Missouri Supreme Court unanimously upholds a 2020 amendment to the state's constitution that expanded Medicaid eligibility.
Over the past few decades, AMMs have diversified rapidly and their design principles, properties, and characterization methods have been outlined more clearly. A major starting point for the design of AMMs is to exploit the existing modes of motion in molecules. For instance, single bonds can be visualized as axes of rotation, as can be metallocene complexes. Bending or V-like shapes can be achieved by incorporating double bonds, that can undergo cis-trans isomerization in response to certain stimuli (typically irradiation with a suitable wavelength), as seen in numerous designs consisting of stilbene and azobenzene units. Similarly, ring-opening and -closing reactions such as those seen for spiropyran and diarylethene can also produce curved shapes. Another common mode of movement is the circumrotation of rings relative to one another as observed in mechanically interlocked molecules (primarily catenanes). While this type of rotation can not be accessed beyond the molecule itself (because the rings are confined within one another), rotaxanes can overcome this as the rings can undergo translational movements along a dumbbell-like axis. Another line of AMMs consists of biomolecules such as DNA and proteins as part of their design, making use of phenomena like protein folding and unfolding.
The resulting Treaty of Córdoba, which was signed on 24 August, kept all existing laws, including the 1812 Constitution, in force until a new constitution for Mexico could be written. O'Donojú became part of the provisional governing junta until his death on 8 October. Both the Spanish Cortes and Ferdinand VII rejected the Treaty of Córdoba, and the final break with the mother country came on 19 May 1822, when the Mexican Congress conferred the throne on Iturbide. Spain initiated attempts to reconquer Mexico and it did not recognize Mexico's independence until 1836. Central America gained its independence along with New Spain. On 15 September 1821, an Act of Independence was signed in Guatemala City which declared Central America (Guatemala, Honduras, El Salvador, Nicaragua, and Costa Rica) independent from Spain. The regional elites supported the terms of the Plan of Iguala and orchestrated the union of Central America with the Mexican Empire in January 1822. One years later, following Iturbide's downfall, the region, with the exception of Chiapas, peacefully seceded from Mexico on 1 July 1823, establishing the Federal Republic of Central America. The new state existed for seventeen years, centrifugal forces pulling the individual provinces apart by 1840.
Acetylcysteine was patented in 1960 as a mucolytic agent. In the 1960s, it was used for managing the mucous symptoms of illnesses including cystic fibrosis, asthma, and chronic bronchitis, as well as other uses, such as a chelating agent in gold therapy. In the late 1960s, the popularity of acetaminophen led to an increase in overdose hepatotoxicity. In 1974, it was discovered that the mechanism was oxidation via cytochrome P450, and administering glutathione-like reducing agents, such as IV cysteine, or oral methionine, were successful in preventing hepatotoxicity. In the US, the then-common formulation of NAC was not certified as pyrogen-free, and thus not approved for IV use. The producer, Mead Johnson, was unwilling to take the expense of certification. In 1977, there was the first case report of oral NAC preventing acetaminophen overdose hepatoxicity in the US. Meanwhile, in the UK, IV NAC (trade name, Parvolex) was found to be more effective and has less side effect than IV cysteamine (associated with a "general feeling of misery") or methionine. There was a dispute concerning whether the oral NAC and the IV NAC is more effective, with the conclusion reached in 1999, that they are roughly equally effective. Another producer finally obtained approval for the IV form of NAC (trade name, Acetadote) in the US in 2004. Amazon removed acetylcysteine for sale in the US in 2021, due to claims by the Food and Drug Administration (FDA) of it being classified as a drug rather than a supplement.
Sources: en.wikipedia.org
Calibration of the system was carried out initially using a flight of mostly civilian-flown, impressed Avro Rota autogyros flying over a known landmark, the radar then being calibrated so that the position of a target relative to the ground could be read off the CRT. The Rota was used because of its ability to maintain a relatively stationary position over the ground, the pilots learning to fly in small circles while remaining at a constant ground position, despite a headwind. The rapid expansion of the CH network necessitated more technical and operational personnel than the UK could provide, and in 1940, a formal request was made by the British High Commission, Ottawa to the Canadian Government, appealing for men skilled in radio technology for the service of the defence of Great Britain. By the end of 1941, 1,292 trained personnel had enlisted and most were rushed to England to serve as radar mechanics.
==== Temporary spacer ==== A synthetic material may be used as a temporary antibiotic spacer before being replaced by a more permanent material. For example, the Masquelet procedure consists of initially using PMMA mixed with an antibiotic (vancomycin or gentamicin) for 4–12 weeks, and then replacing the space with an autologous bone graft. It can be used to treat posttraumatic bone defects.
The boiling point of a solution of an involatile solute is higher than that of the pure solvent, and the boiling-point elevation (ΔT) is directly proportional to the amount concentration for dilute solutions. When the composition is expressed as a molality, the proportionality constant is known as the ebullioscopic constant (Kb) and is characteristic for each solvent. If w represents the mass fraction of the solute in solution, and assuming no dissociation of the solute, the molar mass is given by
We Happy Few is an action-adventure video game developed by Compulsion Games and published by Gearbox Publishing. In 2016, an early access version was released for Windows, with the full game seeing wide release for PlayStation 4, Windows, and Xbox One in August 2018. Played from a first-person perspective, the game combines role-playing, survival, and light roguelike elements. Taking place within the retro-futuristic version of the mid-1960s, following an alternative version of World War II, players take control over one of three characters, each of whom seek to complete a personal task while escaping the fictional city of Wellington Wells – a crumbling dystopia on the verge of societal collapse, due to the overuse of a hallucinogenic drug that keeps its inhabitants blissfully unaware about the truth of their world, while leaving them easily manipulated and lacking morals. The developers focused on creating a story with strong narratives, while underlining gameplay with a sense of paranoia, and designing in-game decisions that are of moral gray areas and weight, which influence and affect later parts of We Happy Few. Design of the game's setting was based on various elements of 1960s British culture, with developer Compulsion Games seeking inspiration on dystopian societies from various influences in the media, such as Brazil, Nineteen Eighty-Four, Animal Farm, Fahrenheit 451, Brave New World, and heavily on the MaddAddam trilogy.
YouTube: Nematocysts Firing YouTube:My Anemone Eat Meat Defensive and feeding behaviour of sea anemone Cnidaria - Guide to the Marine Zooplankton of south eastern Australia, Tasmanian Aquaculture & Fisheries Institute Cnidaria page at Tree of Life Fossil Gallery: Cnidarians Archived 2007-10-24 at the Wayback Machine Hexacorallians of the World
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.